|
|
|
|
|
|
ThromboGenics specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows:
- sales of licenses (99.9%);
- royalties (0.1%).
|
|
| Surperformance© rating of THROMBOGENICS | |
|
|
Overall rating |
In sector |
In country |
| Trading Rating |
|
|
|
| Investor Rating |
|
|
|
| Growth (Revenue) |
|
|
|
| Valuation |
|
|
|
| Finances |
|
|
|
| Profitability |
|
|
|
| Earnings quality |
|
|
|
| Business Predictability |
|
|
|
| PER |
|
|
|
| Potential |
|
|
|
| Yield |
- |
- |
- |
| Consensus |
|
|
|
| 7 days EPS revision |
|
|
|
| 4 months EPS revision |
|
|
|
| 1 year EPS revision |
|
|
|
| 4 months Revenue revision |
|
|
|
| 1 year Revenue revision |
|
|
|
| |
|
|
|
|
Data source :
© 2013 Thomson Reuters |
|
Ratings :
© 2013 Surperformance |
|
|
|
|
|
| - Mister Thomas Clay |
6,10% |
| - Biggar |
5,90% |
| - Oppenheimer Funds |
3,50% |
| - Mister Landon T. Clay |
3,30% |
|
|
|
|
- Chief Financial Officer :
Chris Buyse |
- Chairman of the Board :
Désiré Collen |
- Chief Executive Officer :
Patrik de Haes |
|
|
| Company contact information |
|
Gaston Geenslaan 1
3001 Leuven
Belgium
Phone : +32 (0) 16 75 13 10
Fax : +32 (0) 16 75 13 11
Internet : http://www.thrombogenics.com
|
|
|
|
- NYSE Euronext Brussels - Compartiment B - BEL 20 / Next 150 |
|
|
|
|
| - ISIN Code : |
BE0003846632 |
| - Bloomberg Code : |
THR:BB |
| - Reuters Code : |
THR.BR |
| - Datastream Code : |
|
|
Financial data source :
© 2013 Cofisem |
|
|
